# US 2012/0252890 A1 · Process and compounds for the manufacture of oseltamivir and analogs thereof, and new antiviral agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252890 A1
- Document ID: US20120252890A1
- Status: Published application
- Kind: A1
- Application number: 13/502,375
- Filed: 2010-10-15
- Published: 2012-10-04
- Earliest claimed: 2009-10-23
- Assignees: Brock University
- Inventors: Tomas Hudlicky; Lukas Werner; Ales Machara
- Web page: https://patentgrep.com/patent/US20120252890A1

## CPC

- C07D 317/46: condensed with one six-membered ring
- A61P 31/16: for influenza or rhinoviruses
- C07C 233/81: having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07D 203/26: condensed with carbocyclic rings or ring systems
- C07D 253/10: Condensed 1,2,4-triazines; Hydrogenated condensed 1,2,4-triazines
- C07D 271/12: condensed with carbocyclic rings or ring systems
- C07D 498/18: Bridged systems
- Y02P 20/55: Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

The present application relates to processes for the preparation of intermediates useful in the manufacture of oseltamivir and the H3PO4 salt of oseltamivir, Tamiflu®. The application further relates to novel intermediate and compounds and oseltamivir analogs and to pharmaceutical compositions comprising said analog compounds. The application further relates to a method of using the novel analogs of oseltamivir to treat or prevent influenza.

## Claims

### Claim 1

A process for the preparation of a compound of formula I:
wherein R1 is CO2Et or a functional group that can be converted to CO2Et;
R2 and R3 are independently, suitable protecting groups, or R2 and R3 are joined to form a suitable protecting group;
R4a and R4b are independently selected from H and a suitable protecting group or R4a and
R4b are joined to form a suitable protecting group;
R5a and R5b are independently selected from H and a suitable protecting group or R5a and
R5b are joined to form a suitable protecting group;
the process comprising:
(i) treating a compound of the formula II, wherein R1, R2, R3, R4a and R4b are as defined in formula I under conditions for the [3,3] oxidative rearrangement of the allylic alcohol to provide a compound of the formula III, wherein R1, R2, R3, R4a and R4b are as defined in formula I,
(ii) converting the compound of the formula III, wherein R1, R2, R3, R4a and R4b are as defined in formula I, to a compound of the formula IV, wherein R1, R2, R3, R4a and R4b are as defined in formula I and R7 is a group that is removed under reduction or hydrogenation reaction conditions or R7 is a suitable acid labile protecting group,
and
(iii) reducing or hydrogenating the compound of the formula IV, optionally in the presence of a suitable protecting group reagent, to provide compounds of the formula I, wherein:
a) R5a and R5b are H when R7 is a group that is removed under reduction or hydrogenation reaction conditions and the suitable protecting group reagent is not present;
b) one of R5a and R5b is H and the other is a suitable protecting group or R5a and R5b are joined to form a suitable protecting group when R7 is a group that is removed under reduction or hydrogenation reaction conditions and the suitable protecting group reagent is present; or
c) one of R5a and R5b is H and the other is a suitable acid labile protecting group when R7 is a suitable acid labile protecting group,
wherein, in the compounds of the formulae I, II, III and/or IV, one or more available hydrogens in R1, R2, R3, R4a, R4b, R5a, R5b and/or R7 is/are optionally replaced with F and/or one or more of available atoms in the compounds of the formulae I, II, III and/or IV is/are optionally replaced with an isotopic label.

### Claim 2 (depends on 1)

The process of claim 1, wherein the conditions for the [3,3] oxidative rearrangement of the allylic alcohol to provide a compound of the formula III comprise chromium oxide as the oxidizing reagent.

### Claim 3 (depends on 2)

The process of claim 2, wherein the chromium oxide is prepared by dissolving chromium trioxide in acetic anhydride under conditions to obtain a homogeneous solution, for example at a temperature of about 50° C. to about 100° C.

### Claim 4 (depends on 2)

The process of claim 2, wherein the conditions for the [3,3] oxidative rearrangement comprise a temperature of about −20° C. to about 20° C., followed by warming to room temperature, in a suitable organic solvent, such as dichloromethane.

### Claim 5 (depends on 1)

The process of claim 1, wherein the compound of the formula III is converted to an oxime, imine or hydrazone of the formula IV by reaction with a suitable ammonia derivative, to provide compounds of formula IV, wherein R7 is selected from alkyl, O-alkyl, aryl, O-aryl, OH, NH(alkyl), N(alkyl)(alkyl) and NH2.

### Claim 6 (depends on 1)

The process of claim 1, wherein the compound of the formula III is converted to the oxime of the formula IV by reacting the compound of formula III with hydroxylamine, for example hydroxy amine hydrochloride, at a temperature of about −20° C. to about 20° C., followed by warming to room temperature, in a suitable organic solvent, such as dichloromethane.

### Claim 7 (depends on 1)

The process of claim 1, wherein the compound of the formula IV is reduced using standard hydrogenation conditions, for example in the presence of hydrogen gas and one or more metal catalysts in a suitable solvent, such as ethanol and water at elevated pressure and at about room temperature.

### Claim 8 (depends on 1)

The process of claim 1, wherein the suitable protecting group reagent is t-butoxycarbonylanhydride [(BOC)2O].

### Claim 9 (depends on 1)

The process of claim 1, wherein R1 in the compounds of the formulae I-IV is CO2C1-3alkyl.

### Claim 10 (depends on 1)

The process of claim 1, wherein R2 and R3 in the compounds of formulae I-IV are linked to form, together with the atoms to which they are attached, a 5-membered ring that is substituted with one or two methyl or ethyl groups.

### Claim 11 (depends on 1)

The process of claim 1, wherein one of R4a and R4b in the compounds of formulae I-IV is C1-4acyl and the other is H.

### Claim 12 (depends on 1)

The process of claim 1, wherein one of R5a and R5b in the compounds of formulae I-IV is H or t-butoxycarbonyl, and the other is H.

### Claim 13

A process for the preparation of a compound of formula I:
wherein R1 is CO2Et or a functional group that can be converted to CO2Et;
R2 and R3 are independently, suitable protecting groups, or R2 and R3 are joined to form a suitable protecting group;
R4a and R4b are independently selected from H and a suitable protecting group or R4a and R4b are joined to form a suitable protecting group;
R5a and R5b are independently selected from H and a suitable protecting group or R5a and R5b are joined to form a suitable protecting group;
the process comprising:
(i) treating a compound of the formula II, wherein R1, R2, R3, R4a and R4b are as defined in formula I under conditions for the [3,3] oxidative rearrangement of the allylic alcohol to provide a compound of the formula III, wherein R1, R2, R3, R4a and R4b are as defined in formula I,
(ii) converting the compound of the formula III, wherein R1, R2, R3, R4a and R4b are as defined in formula I, to a compound of the formula IV, wherein R1, R2, R3, R4a and R4b are as defined in formula I and R7 is a group that is removed under reduction or hydrogenation reaction conditions or R7 is a suitable acid labile protecting group,
and
(iii) reducing or hydrogenating the compound of the formula IV, optionally in the presence of a suitable protecting group reagent, to provide compounds of the formula I, wherein:
a) R5a and R5b are H when R7 is a group that is removed under reduction or hydrogenation reaction conditions and the suitable protecting group reagent is not present;
b) one of R5a and R5b is H and the other is a suitable protecting group or R5a and R5b are joined to form a suitable protecting group when R7 is a group that is removed under reduction or hydrogenation reaction conditions and the suitable protecting group reagent is present; or
c) one of R5a and R5b is H and the other is a suitable acid labile protecting group when R7 is a suitable acid labile protecting group,
wherein, in the compounds of the formulae I, II, III and/or IV, one or more available hydrogens in R1, R2, R3, R4a, R4b, R5a, R5b and/or R7 is/are optionally replaced with F and/or one or more of available atoms in the compounds of the formulae I, II, III and/or IV is/are optionally replaced with an isotopic label.

### Claim 14

A compound of the formula III:
wherein R1 is CO2Et or a functional group that can be converted to CO2Et;
R2 and R3 are independently selected from H and a suitable protecting group, or R2 and
R3 are joined to form a suitable protecting group; and
R4a and R4b are independently selected from H and a suitable protecting group or R4a and
R4b are joined to form a suitable protecting group;
wherein, one or more available hydrogens in R1, R2, R3, R4a and/or R4b is/are optionally replaced with F and/or one or more of available atoms is/are optionally replaced with an isotopic label,
or a salt and/or solvate thereof.

### Claim 15

A compound of the formula IV:
wherein R1 is CO2Et or a functional group that can be converted to CO2Et;
R2 and R3 are independently selected from H and a suitable protecting group, or R2 and
R3 are joined to form a suitable protecting group;
R4a and R4b are independently selected from H and a suitable protecting group or R4a and
R4b are joined to form a suitable protecting group; and
R7 is a group that is removed under reduction or hydrogenation reaction conditions or R7 is a suitable acid labile protecting group,
wherein, one or more available hydrogens in R1, R2, R3, R4a, R4b and/or R7 is/are optionally replaced with F and/or one or more of available atoms is/are optionally replaced with an isotopic label,
or a salt, solvate and/or prodrug thereof.

### Claim 16 (depends on 14)

The compound of claim 14, wherein R1 is CO2C1-3alkyl.

### Claim 17 (depends on 14)

The compound of claim 14, wherein R2 and R3 are linked to form, together with the atoms to which they are attached, a 5-membered ring that is substituted with one or two methyl or ethyl groups.

### Claim 18 (depends on 14)

The compound of claim 14, wherein one of R4a and R4b is C1-4acyl and the other is H.

### Claim 19 (depends on 14)

The compound of claim 14, one of R5a and R5b is H or t-butoxycarbonyl, and the other is H.

### Claim 20 (depends on 15)

The compound of claim 15, wherein R7 is selected from R, OR, OH, NH(alkyl), N(alkyl)(alkyl), NH2 and Si(R)3, wherein each R is, independently, lower alkyl or aryl.

### Claim 21 (depends on 14)

A compound of the formula III
wherein R1, R2, R3, R4a and R4b are as defined in claim 14.

### Claim 22 (depends on 21)

The compound of claim 21 that is (3aR,7S,7aS)-ethyl-7-acetamido-2,2-dimethyl-6-oxo-3a,6,7,7a-tetrahydrobenzo[d][1,3]dioxole-4-carboxylate (compound 7), or a solvate thereof.

### Claim 23 (depends on 15)

A compound of the formula IV:
wherein R1, R2, R3, R4a, R4b and R7 are as defined in claim 15.

### Claim 24 (depends on 23)

The compound of claim 23 that is (3aR,7R,7aS)-ethyl-7-acetamido-6-(hydroxyimino)-2,2-dimethyl-3a,6,7,7a-tetrahydrobenzo[d][1,3]dioxole-4-carboxylate
(compound 8), or a solvate thereof.

### Claim 25

A compound of formula V:
wherein
R10 and R11 are independently selected from H, C1-6alkyl and C1-6acyl, or R10 and R11 are joined, together with the atoms to which they are attached, to form a 5-10-membered ring that is unsubstituted or substituted with one or more of halo or C1-6alkyl;
R12a and R12b are independently selected from H, C1-6alkyl and C1-6acyl;
R13 is selected from OR14 and NR15aR15b or R13 is ═O or ═NR16;
R14 is selected from H, C1-6alkyl and C1-6acyl;
R15a and R15b are independently selected from H, C1-6alkyl and C1-6acyl;
R16 is selected from H, OH, C1-6alkyl, OC1-6alkyl, C1-6acyl, OC1-6acyl, NH2, NHC1-6alkyl, N(C1-6alkyl)(C1-6alkyl) and NHC1-6acyl, or
R16 and one of R12a and R12b form a linker group “-A-C(O)-” to provide a compound of the formula:
wherein A is O or NH;
X+ is a cation;
and
one or more available hydrogens in R10, R11, R12a, R12b, R13, R14, R15a, R15b and/or R16 is/are optionally replaced with F and/or one or more of available atoms in the compounds of the formula is/are optionally replaced with an isotopic label,
or a pharmaceutically acceptable salt, and/or solvate thereof.

### Claim 26 (depends on 25)

The compound of claim 25, wherein R10 and R11 are independently selected from H, C1-4alkyl and C1-4acyl, or R10 and R11 are joined, together with the atoms to which they are attached, to form a 5-6-membered ring that is unsubstituted or substituted with one or more of halo or C1-4alkyl.

### Claim 27

(canceled)

### Claim 28 (depends on 26)

The compound of claim 26, wherein R10 and R11 are joined, together with the atoms to which they are attached, to form a 5-membered ring that is unsubstituted or substituted with one or two Me.

### Claim 29 (depends on 25)

The compound of claim 25, wherein R12a and R12b are independently selected from H, C1-4alkyl and C1-4acyl.

### Claim 30

(canceled)

### Claim 31 (depends on 29)

The compound of claim 29, wherein one of R12a and R12b is H and the other is selected from Me, Et, C(O)Me and C(O)Et.

### Claim 32

(canceled)

### Claim 33 (depends on 25)

The compound claim 25, wherein R13 is selected from OR11 or R13 is ═NR16, where R14 is selected from H, C1-4alkyl and C1-4acyl and R16 is selected from H, OH, C1-4alkyl, OC1-4alkyl, C1-4acyl, OC1-4acyl NH2, NHC1-4alkyl, N(C1-4alkyl)(C1-4alkyl) and NHC1-4acyl.

### Claim 34 (depends on 33)

The compound of claim 33, wherein R13 is selected from OR11 or R13 is ═NR16, where R14 is selected from H, Me, Et, C(O)Me and C(O)Et and R16 is selected from H, OH, Me, Et, OMe, OEt, C(O)Me, C(O)Et, OC(O)Me, OC(O)Et, NH2, NHMe, NHEt, N(Me)2, N(Et)2, NHC(O)Me and NH(C(O)Et.

### Claim 35

(canceled)

### Claim 36 (depends on 25)

The compound of claim 25, wherein R16 and one of R12a and R12b form a linker group “-A-C(O)-” to provide a compound of the formula:
wherein A is O.

### Claim 37 (depends on 36)

The compound of claim 36, wherein R12 is C1-6acyl.

### Claim 38 (depends on 25)

The compound claim 25, wherein X+ is an alkali metal cation.

### Claim 39

(canceled)

### Claim 40 (depends on 25)

A compound of the formula V:
wherein R10, R11, R12a, R12b, R13 and X+ are as defined in claim 25, and
one or more available hydrogens in R10, R11, R12a, R12b, R13, R14, R15a, R15b and/or R16 is/are optionally replaced with F and/or one or more of available atoms in the compounds of the formula is/are optionally replaced with an isotopic label,
or a pharmaceutically acceptable salt, and/or solvate thereof.

### Claim 41 (depends on 25)

The compound of claim 25, wherein the compound of formula V is:
sodium (3aR,6R,7R,7aS)-7-acetamido-6-hydroxy-2,2-dimethyl-3a,6,7,7a-tetrahydrobenzo[d][1,3]dioxole-4-carboxylate (compound 19) or an alternate pharmaceutically acceptable salt thereof and/or a solvate thereof.

### Claim 42

(canceled)

### Claim 43 (depends on 40)

The compound of claim 40, that is sodium (3aR,7R,7aS,E)-7-acetamido-6-(hydroxyimino)-2,2-dimethyl-3a,6,7,7a-tetrahydrobenzo[d][1,3]dioxole-4-carboxylate (compound 17), or an alternate pharmaceutically acceptable salt thereof and/or a solvate and/or prodrug thereof.

### Claim 44 (depends on 43)

The compound of claim 43, wherein the prodrug of the compound of formula V is the corresponding acid, C1-20alkyl ester, C6-14aryl ester or C1-6alkyleneC6-14aryl ester.

### Claim 45

A compound of the formula VI:
wherein
R16 and R17 are independently selected from H, C1-6alkyl and C1-6acyl, or R16 and R17 are joined together to form, together with the atoms to which they are attached, a 5-10-membered ring that is unsubstituted or substituted with one or more of halo or C1-4alkyl;
R18a and R18b are independently selected from H, C1-6alkyl and C1-6acyl;
R19 is selected from H, C1-6alkyl and C1-6acyl;
Z+ is a cation; and
one or more available hydrogens in R16, R17, R18a, R18b and/or R19 is/are optionally replaced with F and/or one or more of available atoms in the compounds of the formula is/are optionally replaced with an isotopic label,
or a pharmaceutically acceptable salt, and/or solvate thereof.

### Claim 46 (depends on 45)

The compound of claim 45, wherein R16 and R17 are independently selected from H, C1-4alkyl and C1-4acyl, or R16 and R17 are joined, together with the atoms to which they are attached, to form a 5-6-membered ring that is unsubstituted or substituted with one or more of halo or C1-4alkyl.

### Claim 47 (depends on 46)

The compound of claim 46, wherein R16 and R17 are independently selected from H, Me, Et, C(O)Me and C(O)Et, or R16 and R17 are joined, together with the atoms to which they are attached, to form a 5-6-membered ring that is unsubstituted or substituted with one or two Me or Et.

### Claim 48

(canceled)

### Claim 49 (depends on 45)

The compound of claim 45, wherein R18a and R18b are independently selected from H, C1-4alkyl and C1-4acyl.

### Claim 50 (depends on 49)

The compound of claim 49, wherein R18a and R18b are independently selected from H, Me, Et, C(O)Me and C(O)Et.

### Claim at position 51

-52. (canceled)

### Claim 53 (depends on 45)

The compound of claim 45, wherein R19 is selected from H, C1-4alkyl and C1-4acyl.

### Claim 54 (depends on 53)

The compound of claim 53, wherein R19 is selected from H, Me, Et, C(O)Me and C(O)Et.

### Claim 55

(canceled)

### Claim 56 (depends on 45)

The compound of claim 45, wherein Z+ is an alkali metal cation.

### Claim 57

(canceled)

### Claim 58 (depends on 45)

A compound of formula IV:
wherein R16, R16, R18a, R18b, R19 and Z+ are as defined in claim 45, and
one or more available hydrogens in R10, R11, R12a, R12b, R13, R16, R16, R18a, R18b and/or R19 is/are optionally replaced with F and/or one or more of available atoms is/are optionally replaced with an isotopic label,
or a pharmaceutically acceptable salt and/or solvate thereof.

### Claim 59 (depends on 45)

The compound of claim 45, wherein the compound of formula VI is sodium (3aS,4S,7R,7aS)-7-acetamido-4-hydroxy-2,2-dimethyl-3a,4,7,7a-tetrahydrobenzo[d][1,3]dioxole-4-carboxylate (compound 16) or an alternate pharmaceutically acceptable salt thereof and/or a solvate thereof.

### Claim at position 59

-62. (canceled)

### Claim 63

A method of treating or preventing influenza comprising administering an effective amount of one or more compounds of the formula V or VI:
wherein
R10 and R11 are independently selected from H, C1-6alkyl and C1-6 acyl, or R10 and R11 are joined, together with the atoms to which they are attached, to form a 5-10-membered ring that is unsubstituted or substituted with one or more of halo or C1-6alkyl;
R12a and R12b are independently selected from H, C1-6alkyl and C1-6acyl;
R13 is selected from OR14 and NR15aR15b or R13 is ═O or ═NR16;
R14 is selected from H, C1-6alkyl and C1-6acyl;
R15a and R15b are independently selected from H, C1-6alkyl and C1-6acyl;
R16 is selected from H, OH, C1-6alkyl, OC1-6alkyl, C1-6acyl, OC1-6acyl, NH2, NHC1-6alkyl, N(C1-6alkyl)(C1-6alkyl) and NHC1-6acyl, or
R16 and one of R12a and R12b form a linker group “-A-C(O)-” to provide a compound of the formula:
wherein A is O or NH;
X+ is a cation;
and
one or more available hydrogens in R10, R11, R12a, R12b, R13, R14, R15a, R15b and/or R16 is/are optionally replaced with F and/or one or more of available atoms in the compounds of the formula is/are optionally replaced with an isotopic label,
or a pharmaceutically acceptable salt, and/or solvate thereof; or
wherein
R16 and R17 are independently selected from H, C1-6alkyl and C1-6acyl, or R16 and R17 are joined together to form, together with the atoms to which they are attached, a 5-10-membered ring that is unsubstituted or substituted with one or more of halo or C1-4alkyl;
R18a and R18b are independently selected from H, C1-6alkyl and C1-6acyl;
R19 is selected from H, C1-6alkyl and C1-6acyl;
Z+ is a cation; and
one or more available hydrogens in R16, R17, R18a, R18b and/or R19 is/are optionally replaced with F and/or one or more of available atoms in the compounds of the formula is/are optionally replaced with an isotopic label,
or a pharmaceutically acceptable salt, and/or solvate thereof, to a subject in need thereof.

### Claim 64

A pharmaceutical composition comprising one or more compounds of the formula V or VI;
wherein
R10 and R11 are independently selected from H, C1-6alkyl and C1-6acyl, or R10 and R11 are joined, together with the atoms to which they are attached, to form a 5-10-membered ring that is unsubstituted or substituted with one or more of halo or C1-6alkyl;
R12a and R12b are independently selected from H, C1-6alkyl and C1-6acyl;
R13 is selected from OR14 and NR15aR15b or R13 is ═O or ═NR16;
R14 is selected from H, C1-6alkyl and C1-6acyl;
R15a and R15b are independently selected from H, C1-6alkyl and C1-6acyl;
R16 is selected from H, OH, C1-6alkyl, OC1-6alkyl, C1-6acyl, OC1-6acyl, NH2, NHC1-6alkyl, N(C1-6alkyl)(C1-6alkyl) and NHC1-6acyl, or
R16 and one of R12a and R12b form a linker group “-A-C(O)-” to provide a compound of the formula:
wherein A is O or NH;
X+ is a cation;
and
one or more available hydrogens in R10, R11, R12a, R12b, R13, R14, R15a, R15b and/or R16 is/are optionally replaced with F and/or one or more of available atoms in the compounds of the formula is/are optionally replaced with an isotopic label,
or a pharmaceutically acceptable salt, and/or solvate thereof; or
wherein
R16 and R17 are independently selected from H, C1-6alkyl and C1-6acyl, or R16 and R17 are joined together to form, together with the atoms to which they are attached, a 5-10-membered ring that is unsubstituted or substituted with one or more of halo or C1-4alkyl;
R18a and R18b are independently selected from H, C1-6alkyl and C1-6acyl;
R19 is selected from H, C1-6alkyl and C1-6acyl;
Z+ is a cation; and
one or more available hydrogens in R16, R17, R18a, R18b and/or R19 is/are optionally replaced with F and/or one or more of available atoms in the compounds of the formula is/are optionally replaced with an isotopic label,
or a pharmaceutically acceptable salt, and/or solvate thereof,
and a pharmaceutically acceptable carrier and/or diluent.

### Claim 65 (depends on 15)

The compound of claim 15, wherein R1 IV is CO2C1-3alkyl.

### Claim 66 (depends on 15)

The compound of claim 15, wherein R2 and R3 are linked to form, together with the atoms to which they are attached, a 5-membered ring that is substituted with one or two methyl or ethyl groups.

### Claim 67 (depends on 15)

The compound of claim 15, wherein one of R4a and R4b is C1-4acyl and the other is H.

### Claim 68 (depends on 15)

The compound of claim 15, one of R5a and R5b is H or t-butoxycarbonyl, and the other is H.
